TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11932866

Group type: EXPERIMENTAL
Intervention: Prosthesis fitted with TT Pylon (ProsWith)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Prosthesis without TT Pylon (ProsWithout)
Number of subjects: 6
Study: 9610454

Group type: EXPERIMENTAL
Intervention: Systemic diclofenac sodium 50 mg given orally 1 hour before surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no diclofenac)
Number of subjects: 100
Study: 7804666

Group type: EXPERIMENTAL
Intervention: Tiapride (100 mg three times a day for at least one month)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 3243926

Group type: EXPERIMENTAL
Intervention: Intravenous ranitidine (50 mg over 5 minutes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine (not directly studied but referenced)
Number of subjects: 0
Study: 11396641

Group type: EXPERIMENTAL
Intervention: Innovative techniques and promising new drugs for the treatment of advanced epithelial ovarian cancer
Number of subjects: 0
Study: 30646291

Group type: COMPARATOR
Intervention: Control group (n=196)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Group A (n=143)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Group B (n=128)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Group C (n=131)
Number of subjects: 598
Study: 27256816

Group type: EXPERIMENTAL
Intervention: Women's Lifestyle Physical Activity Program with 11 motivational interviewing personal calls (PCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women's Lifestyle Physical Activity Program with 11 automated motivational message calls (ACs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Women's Lifestyle Physical Activity Program with no calls (Control)
Number of subjects: 0
Study: 24829038

Group type: EXPERIMENTAL
Intervention: Specialized multidisciplinary tinnitus treatment based on cognitive behavioral therapy
Number of subjects: 492

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 492
Study: 23242019

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg intravenously twice a day for fasting time, then 40 mg orally twice a day until discharge
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-pantoprazole (control group)
Number of subjects: 40
Study: 20152243

Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin (10/20 mg) plus niacin (to 2 g)
Number of subjects: 942

Group type: COMPARATOR
Intervention: Ezetimibe/simvastatin (10/20 mg)
Number of subjects: 942
Study: 18817156

Group type: EXPERIMENTAL
Intervention: Remifentanil (1 mic kg(‐1) followed by 0.5 mic kg(‐1) min(‐1) i.v)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alfentanil (20 mic kg(‐1) followed by 2 mic kg(‐1) min(‐1) i.v)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined sciatic-femoral nerve block with ropivacaine 25 mL 0.75 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Remifentanil and Alfentanil groups
Number of subjects: 60
Study: 16105518

Group type: EXPERIMENTAL
Intervention: Practicing the entire task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blocked practice
Number of subjects: 0
Study: 11978684

Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp)
Number of subjects: 2420

Group type: COMPARATOR
Intervention: Human insulin (HI)
Number of subjects: 2420
Study: 10367507

Group type: EXPERIMENTAL
Intervention: Billroth I (BI)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Billroth II (BII)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Roux en Y (Y)
Number of subjects: 45
Study: 8775644

Group type: EXPERIMENTAL
Intervention: C‐RPE trial
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: P‐RPE trial
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HR trial
Number of subjects: 10
Study: 2279254

Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg t.i.d.) for 3 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ibopamine (300 mg daily for 3 weeks)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 41542

Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Quinalbarbitone 200 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Temazepam 15 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Flurazepam 15 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Quinalbarbitone 100 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30646926

Group type: EXPERIMENTAL
Intervention: LOWFODMAP diet (16.06 ± 1.79 g·d‐ 1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: LOWFODMAP diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: HIGHFODMAP diet (38.65 ± 6.66 g·d‐ 1)
Number of subjects: 16
Study: 29577324

Group type: EXPERIMENTAL
Intervention: Stored autologous RBC transfusion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fresh RBC transfusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Stored RBC transfusion
Number of subjects: 18
Study: 27230850

Group type: EXPERIMENTAL
Intervention: LCZ696 400 mg once daily (QD) on days 1 and 5 in patients with mild renal impairment (N=8)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LCZ696 400 mg once daily (QD) on days 1 and 5 in patients with moderate renal impairment (N=8)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LCZ696 400 mg once daily (QD) on days 1 and 5 in patients with severe renal impairment (N=6)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy subjects (CrCl >80 mL/min)
Number of subjects: 30
Study: 25098025

Group type: EXPERIMENTAL
Intervention: r-hLH 2,750 IU
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: r-hLH 5,500 IU
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: r-hLH 11,000 IU
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: u-hCG 5,000 IU
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: r-hLH 825 IU
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: r-hLH 22,000 IU
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 67
Study: 21935705

Group type: EXPERIMENTAL
Intervention: Vorapaxar 20 mg
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Vorapaxar 40 mg
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Vorapaxar 5 mg/day
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Vorapaxar 1 mg/day
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Vorapaxar 3 mg/day
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 21122285

Group type: EXPERIMENTAL
Intervention: Therapy with ESWT (shock waves) and proprioceptive Multi Joint System, along with a specific nutritional supplement.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nutritional supplement in Group B2.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Group B1 without nutritional supplement).
Number of subjects: 80
Study: 17438307

Group type: EXPERIMENTAL
Intervention: Exercise training (three 60-minute sessions per week for 4 months)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untrained hypertensive patients
Number of subjects: 20
Study: 15854093

Group type: EXPERIMENTAL
Intervention: Reinforced sternal-closure system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard stainless steel wires (Control)
Number of subjects: 40
Study: 12378386

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 207

Group type: COMPARATOR
Intervention: No diabetes (Control)
Number of subjects: 207
Study: 11232674

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg once a day in the evening
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg once a day in the morning
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg b.i.d.
Number of subjects: 120
Study: 9923581

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg orally once daily for 5 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8151602

Group type: EXPERIMENTAL
Intervention: Nocturnal BP monitoring every 15 minutes (session A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nocturnal BP monitoring every 60 minutes (session B)
Number of subjects: 24
Study: 3045100

Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Stepwise multiple regression analysis
Number of subjects: 70
Study: 31806133

Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 16740
Study: 29173320

Group type: EXPERIMENTAL
Intervention: Children born extremely prematurely
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Children born prematurely with BPD
Number of subjects: 303

Group type: COMPARATOR
Intervention: Children born at term
Number of subjects: 303
Study: 25466664

Group type: EXPERIMENTAL
Intervention: Diet containing foods enriched with ω‐3 fatty acids, β‐glucans, phytosterols, and vitamin E
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isoenergetic diet without the active components
Number of subjects: 16
Study: 23522354

Group type: EXPERIMENTAL
Intervention: Neusidl Corneal Inserter (Fischer Surgical Inc)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Charlie II insertion forceps (Bausch & Lomb Surgical)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 79
Study: 21410371

Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytarabine (200 mg/m² continuous IV infusion for 24 hours in cycle 1 and 1000 mg/m² by infusion for 3 hours twice daily in cycle 2)
Number of subjects: 860

Group type: COMPARATOR
Intervention: High-dose cytarabine (1000 mg/m² every 12 hours in cycle 1 and 2000 mg/m² twice daily in cycle 2)
Number of subjects: 860
Study: 19713849

Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0
Study: 17166332

Group type: EXPERIMENTAL
Intervention: α1-adrenergic receptor antagonists (α1-AR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phosphodiesterase type 5 inhibitors (PDE-5s)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of α1-AR antagonist and PDE-5
Number of subjects: 0
Study: 15909750

Group type: EXPERIMENTAL
Intervention: Ethambutol therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no ethambutol)
Number of subjects: 60
Study: 11883023

Group type: EXPERIMENTAL
Intervention: Ante partum perineal massage
Number of subjects: 4
Study: 9196083

Group type: EXPERIMENTAL
Intervention: rhuMAb-E25 (2 mg/kg on Day 0 and 1 mg/kg on Days 7, 14, 28, 42, 56, and 70)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 8308939

Group type: EXPERIMENTAL
Intervention: Traditional alcoholism treatment for alcohol and cocaine abusers
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional alcoholism treatment for alcohol-only patients
Number of subjects: 100
Study: 3083718

Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg nicardipine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 0.02 mg/kg nicardipine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg nicardipine
Number of subjects: 47
Study: 31796488

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral FCR intervention consisting of an intake with the GP and five sessions with the MHW.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 0
Study: 30021518

Group type: EXPERIMENTAL
Intervention: Intragastric Balloon (IB)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Duodenal-Jejunal Bypass Liner (DJBL)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All groups (IB, DJBL, Sham)
Number of subjects: 150
Study: 26563940

Group type: EXPERIMENTAL
Intervention: Nano-structured doxycycline films
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Doxycycline films
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo films
Number of subjects: 150
Study: 25486273

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) - 1 minute at ∼ 100% W peak and 1 minute at ∼ 20% W peak for 20 minutes
Number of subjects: 44

Group type: COMPARATOR
Intervention: Continuous Moderate-Intensity Exercise (CMI) - ∼ 40% W peak for 40 minutes
Number of subjects: 44

Group type: COMPARATOR
Intervention: Continuous Vigorous-Intensity Exercise (CVI) - ∼ 80% W peak for 20 minutes
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: HIT
Number of subjects: 44
Study: 21604211

Group type: EXPERIMENTAL
Intervention: Caloric restriction diet combined with aerobic exercises
Number of subjects: 40

Group type: COMPARATOR
Intervention: Caloric restriction diet
Number of subjects: 40
Study: 21059586

Group type: EXPERIMENTAL
Intervention: Expressive writing intervention
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual-care control condition
Number of subjects: 57
Study: 17701271

Group type: EXPERIMENTAL
Intervention: Bright light therapy (10,000 lux, n = 10)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Dim red light (600 lux, n = 5)
Number of subjects: 15
Study: 15860501

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (ganirelix) administered daily from the 8th day of stimulation
Number of subjects: 148

Group type: COMPARATOR
Intervention: GnRH agonist (triptorelin) long protocol
Number of subjects: 148
Study: 12595851

Group type: EXPERIMENTAL
Intervention: Dobutamine (mean dose 4.1 +/- 1.4 microg/kg/min)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Milrinone (mean dose 0.39 +/- 1.0 microg/kg/min)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Milrinone
Number of subjects: 36
Study: 10528419

Group type: EXPERIMENTAL
Intervention: Acarbose 300 mg per day for 24 weeks
Number of subjects: 76
Study: 7860736

Group type: EXPERIMENTAL
Intervention: myo-inositol in cerebrospinal fluid (CSF)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: myo-inositol in plasma
Number of subjects: 10

Group type: COMPARATOR
Intervention: CSF concentrations of mannitol, sorbitol, galactitol, ribitol, arabitol, or 1,5-anhydrosorbitol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: plasma mannitol, ribitol, and arabitol
Number of subjects: 10
Study: 1683336

Group type: EXPERIMENTAL
Intervention: Zotepine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Perazine
Number of subjects: 41
Study: 7084138

Group type: EXPERIMENTAL
Intervention: Oral information about medications at initial interview
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Written information to take home
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Telephone contact only
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination of oral and written information
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study: 3971235

Group type: EXPERIMENTAL
Intervention: Antiphlebitic mixture of heparin‐hydrocortisone‐sodium bicarbonate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31862762

Group type: EXPERIMENTAL
Intervention: Prophylactic prednisone
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control (no prophylactic prednisone)
Number of subjects: 153
Study: 28987341

Group type: EXPERIMENTAL
Intervention: Immediate group intervention
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Delayed group intervention
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Overall intervention effectiveness
Number of subjects: 1700
Study: 26350486

Group type: EXPERIMENTAL
Intervention: Baseline depression/anxiety symptoms
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Persistent depression/anxiety symptoms
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Patients with symptoms of depression/anxiety at baseline
Number of subjects: 379
Study: 24762026

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention including motivational aspects, cognitive aspects, and training in inhalation techniques
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 146
Study: 22609118

Group type: EXPERIMENTAL
Intervention: Self-reported height
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Self-reported weight
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Self-reported BMI
Number of subjects: 125
Study: 20406512

Group type: EXPERIMENTAL
Intervention: SpiroPro pneumotachometer tube after 5-9 disinfections
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SpiroPro pneumotachometer tube after 10 disinfections
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rigorous rinsing in distilled water and repeated calibration checks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Single use of SpiroPro pneumotachometers
Number of subjects: 10
Study: 18458872

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 9

Group type: COMPARATOR
Intervention: Healthy volunteers (control)
Number of subjects: 9
Study: 16150608

Group type: EXPERIMENTAL
Intervention: Postural correction during seated typing postures (corrected posture)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Postural correction during standing postures (corrected posture)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Habitual posture during seated typing
Number of subjects: 18

Group type: COMPARATOR
Intervention: Forward head posture during seated typing
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Masseter muscle activation
Number of subjects: 18
Study: 11171713

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9764154

Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 309

Group type: COMPARATOR
Intervention: Sandimmun
Number of subjects: 309
Study: 10155556

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC) with corticosteroids (CS) and plasma exchanges (PE)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Prednisone and PE
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Short-term steroid therapy and PE with anti-viral therapy
Number of subjects: 236

Group type: COMPARATOR
Intervention: Plasma exchanges (PE)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Prednisone in association with CYC
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Anti-viral agents and PE
Number of subjects: 236
Study: 3402096

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 832

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 832
Study: 29928869

Group type: EXPERIMENTAL
Intervention: Focal cryoablation (CRYO)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 46
Study: 26252875

Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg once daily and asunaprevir 100 mg twice daily for 24 weeks
Number of subjects: 230

Group type: COMPARATOR
Intervention: Telaprevir 750 mg three times daily for 12 weeks and peginterferon/ribavirin for 24 weeks
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Daclatasvir + asunaprevir
Number of subjects: 230

Group type: COMPARATOR
Intervention: Telaprevir + peginterferon/ribavirin
Number of subjects: 230
Study: 25313512

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 22551104

Group type: EXPERIMENTAL
Intervention: Urodynamic testing (n=315)
Number of subjects: 630

Group type: COMPARATOR
Intervention: Evaluation only (n=315)
Number of subjects: 630
Study: 20817281

Group type: EXPERIMENTAL
Intervention: Double-dose clopidogrel (600 mg on day 1, 150 mg on days 2-7, then 75 mg daily)
Number of subjects: 17263

Group type: EXPERIMENTAL
Intervention: Double-dose clopidogrel
Number of subjects: 17263

Group type: COMPARATOR
Intervention: Standard-dose clopidogrel (300 mg on day 1 then 75 mg daily)
Number of subjects: 17263

Group type: EXPERIMENTAL
Intervention: High-dose aspirin (300-325 mg daily)
Number of subjects: 17263

Group type: COMPARATOR
Intervention: Low-dose aspirin (75-100 mg daily)
Number of subjects: 17263

Group type: EXPERIMENTAL
Intervention: High-dose aspirin
Number of subjects: 17263

Group type: COMPARATOR
Intervention: Low-dose aspirin
Number of subjects: 17263
Study: 18623043

Group type: EXPERIMENTAL
Intervention: Clindamycin 600 mg oral dose
Number of subjects: 24
Study: 15858525

Group type: EXPERIMENTAL
Intervention: Participant-centered adaptations (tailoring multi-component interventions, using interpersonal contacts for participant maintenance, non-blinding of trial participants)
Number of subjects: 0
Study: 12391441

Group type: EXPERIMENTAL
Intervention: Endurance exercise (20 min at 80% of estimated maximum cardiorespiratory endurance)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (watched a 20 min emotionally neutral video)
Number of subjects: 50
Study: 9448150

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cyclosporine (Control)
Number of subjects: 53
Study: 7611285

Group type: EXPERIMENTAL
Intervention: Written materials
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Video materials
Number of subjects: 346
Study: 2616352

Group type: EXPERIMENTAL
Intervention: Sucralfate pretreatment (1-g dose at 6 and 2 hours before ciprofloxacin)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ciprofloxacin alone
Number of subjects: 12
Study: 328034

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 810
Study: 31237158

Group type: EXPERIMENTAL
Intervention: Transradial access
Number of subjects: 6006

Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 6006

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 6006
Study: 29752024

Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 268896

Group type: EXPERIMENTAL
Intervention: Vaccine plus behavioral change
Number of subjects: 268896

Group type: COMPARATOR
Intervention: Non-intervention
Number of subjects: 268896
Study: 27381900

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 228
Study: 24520906

Group type: EXPERIMENTAL
Intervention: Computerized brief intervention (CBI)
Number of subjects: 360

Group type: COMPARATOR
Intervention: In-person brief intervention (IBI)
Number of subjects: 360